The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.
They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.
With Medicare coverage for the test in place, the company is hoping it will surpass the limited commercial success of its initial Xpresys Lung offering.
Both published last month, the studies looked at, respectively, early-stage discovery of lung cancer markers and development of a clinical test for the disease.
Palmetto GBA has issued a draft local coverage determination for the company's Xpresys Lung 2 lung cancer test, an update version of its original Xpresys test.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The study found that with use of the mass spec-based test, about a third of surgeries and total invasive procedures, including biopsies, could be avoided.
The study suggests Indi's Xpresys test could be useful in physician decision making but raises questions about the extent to which doctors will follow its recommendations.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.